Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Trametinib

2 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCMEL1398

05/23/2014

BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation- Positive Melanoma that has Metastasized to the Brain

Treatment

VICCMELP1388

03/24/2014

A Dose-Escalation, Phase I/II, Open-Label, Three-Part Study of the MEK Inhibitor, trametinib, Combined with the CDK4/6 Inhibitor, palbociclib, To Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity in Subjects with Solid Tumors.